Literature DB >> 27658341

Hypoadiponectinemia, elevated iron and high-sensitivity C-reactive protein levels and their relation with prostate size in benign prostatic hyperplasia.

H Nandeesha1, A Eldhose1, L N Dorairajan1, B Anandhi1.   

Abstract

Elevated iron, high-sensitivity C-reactive protein (CRP) and hypoadiponectinemia are known to initiate tumour development. There is paucity of data regarding the above-mentioned parameters and their relation with prostate size in benign prostatic hyperplasia (BPH). The present study was designed to assess the levels of iron, hs-CRP and adiponectin levels and their association with prostate size in BPH patients. A total of 37 BPH cases and 36 controls were enrolled in the study. Iron, hs-CRP and adiponectin were estimated in both the groups. Iron and hs-CRP were significantly increased and adiponectin was significantly reduced in BPH cases when compared with controls. Iron (r = .397, p = .015), hs-CRP (r = .341, p = .039) and adiponectin (r = -.464, p = .004) were significantly associated with prostate size in BPH cases. Multivariate linear regression analysis showed that iron acts as predictor of prostate size in BPH (R2  = 0.395, β = 0.526, p = .001). We conclude that iron and hs-CRP are elevated and adiponectin is reduced in BPH cases and associated with prostate size.
© 2016 Blackwell Verlag GmbH.

Entities:  

Keywords:  C-reactive protein; adiponectin; benign prostatic hyperplasia; iron; prostate-specific antigen

Mesh:

Substances:

Year:  2016        PMID: 27658341     DOI: 10.1111/and.12715

Source DB:  PubMed          Journal:  Andrologia        ISSN: 0303-4569            Impact factor:   2.775


  2 in total

Review 1.  High altitude exposure affects male reproductive parameters: could it also affect the prostate?†.

Authors:  Diana Elizabeth Alcantara-Zapata; Aníbal J Llanos; Carolina Nazzal
Journal:  Biol Reprod       Date:  2022-03-19       Impact factor: 4.285

2.  Periprostatic fat thickness measured on MRI correlates with lower urinary tract symptoms, erectile function, and benign prostatic hyperplasia progression.

Authors:  Bo Zhang; Xiang Chen; Yu-Hang Liu; Yu Gan; Pei-Hua Liu; Zhi Chen; Wei-Ping Xia; Guo-Yu Dai; Feng Ru; Ze-Xiang Jiang; Yao He
Journal:  Asian J Androl       Date:  2021 Jan-Feb       Impact factor: 3.285

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.